Illinois Tech Journal
SEE OTHER BRANDS

Your science and technology news reporter from Illinois

Illinois Tech Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Tech Journal.

Press releases published on June 23, 2025

Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its biomarker-guided DB104 (liafensine) program to one of Taiwan’s …

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of …

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was …

AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models

AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models

ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated inflammatory diseases Findings reinforce ALTB-268’s ability to downregulate T cell effector function …

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib …

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage …

Built for the Future: TwentyOneVC Supports Investment Planning

Built for the Future: TwentyOneVC Supports Investment Planning

LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- TwentyOneVC, a financial company, has unveiled a new suite of planning tools aimed at helping users build and manage long-term financial strategies with a generational mindset. The update signals a shift in the …

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data demonstrated in Part A of the study for …

Official Launch of Virtune Coinbase 50 Index ETP Marked by Bell Ringing in Frankfurt

Official Launch of Virtune Coinbase 50 Index ETP Marked by Bell Ringing in Frankfurt

Stockholm, June 23, 2025 – Virtune, the Swedish regulated crypto asset manager, celebrated the official launch of its latest exchange-traded product, the Virtune Coinbase 50 Index ETP, with a ceremonial bell ringing at Deutsche Börse Xetra in Frankfurt on …

Officiell lansering av Virtune Coinbase 50 Index ETP markerad med bell ringning i Frankfurt

Officiell lansering av Virtune Coinbase 50 Index ETP markerad med bell ringning i Frankfurt

Stockholm, 23 juni 2025 – Virtune, den svenska reglerade kapitalförvaltaren för kryptotillgångar, firade den 17 juni den officiella lanseringen av sin senaste börshandlade produkt, Virtune Coinbase 50 Index ETP, med en högtidlig bell ringing-ceremoni på …

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global …

LightSolver Selected as 2025 Technology Pioneer by the World Economic Forum

LightSolver Selected as 2025 Technology Pioneer by the World Economic Forum

TEL AVIV, Israel , June 23, 2025 (GLOBE NEWSWIRE) -- LightSolver, inventors of a new laser-based HPC computing paradigm, today announced that it has been named a 2025 Technology Pioneer by the World Economic Forum (WEF). With this recognition, LightSolver …

$PUMPIT Relaunches as $BOG on Pump.fun - Revives Legendary Bogdanoff Crypto Meme Legacy

$PUMPIT Relaunches as $BOG on Pump.fun - Revives Legendary Bogdanoff Crypto Meme Legacy

PARIS, FRANCE, June 23, 2025 (GLOBE NEWSWIRE) -- The spirit of crypto meme culture made a triumphant return with the recent relaunch of $PUMPIT as $BOG, the only memecoin officially backed by the Bogdanoff family and inspired by the iconic legacy of Igor …

BCC Mining cloud mining supports BTC/XRP one-click mining

BCC Mining cloud mining supports BTC/XRP one-click mining

New York City, NY, June 23, 2025 (GLOBE NEWSWIRE) -- Tensions in the Middle East have increased volatility in the cryptocurrency market, and investors are looking for safer ways to hedge their investments. BCC Mining has become a popular investment option …

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability …

EveLab Insight Debuts Dynamic Wrinkle Detection Technology at VivaTech 2025, Shaping the Future of AI-Powered Skin Wellness

EveLab Insight Debuts Dynamic Wrinkle Detection Technology at VivaTech 2025, Shaping the Future of AI-Powered Skin Wellness

SINGAPORE, June 23, 2025 (GLOBE NEWSWIRE) -- EveLab Insight, a global leader in AI skin analysis technology, successfully concluded its debut at VivaTech 2025, Europe's premier innovation and technology event. From June 11-14, the company showcased a major …

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus R2 combination treatment resulted in …

141,959 Orion Corporation A shares converted into B shares

141,959 Orion Corporation A shares converted into B shares

ORION CORPORATION  STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST          141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of …

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

ORION OYJ         PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT          23.6.2025 KLO 9.30          141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 141 959 A- …

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service